This AR-driven mutant was reported to have significantly enhanced viral activity in the presence of bicalutamide both in vitro and in vivo, suggesting a promising novel therapy for both prostate cancer and AR-positive TNBC patients. The gene discussed is AR; the disease is prostate carcinoma.